NCT05345964 - Phase I Study of GST-HG151 Tablets in Healthy Volunteers | Biotech Hunter

Enrollment

112

Participants

Timeline

Start Date

March 7, 2022

Primary Completion Date

March 31, 2023

Study Completion Date

May 31, 2023

Conditions

Healthy Volunteers

Interventions

DRUG

GST-HG151

Subjects will take GST-HG151 orally(once daily) on Day 1

DRUG

Placebo

Subjects will take Placebo orally(once daily) on Day 1

DRUG

GST-HG151

Subjects will take GST-HG151 orally (once daily) from Day 1 to Day 7

DRUG

Placebo

Subjects will take Placebo orally (once daily) from day 1 to day 7

DRUG

GST-HG151

Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 \~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days.

DRUG

GST-HG151

Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 \~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days.

Trial Locations (1)

350025

RECRUITING

Mengchao Hepatpbiliary Hospital of Fujian Medical University, Fujian